Abbvie Inc (ABBV) concluded trading on Wednesday at a closing price of $176.46, with 6.08 million shares of worth about $1.07 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.66% during that period and on December 04, 2024 the price saw a loss of about -2.78%. Currently the company’s common shares owned by public are about 1.77B shares, out of which, 1.77B shares are available for trading.
Stock saw a price change of -2.58% in past 5 days and over the past one month there was a price change of -11.98%. Year-to-date (YTD), ABBV shares are showing a performance of 13.87% which increased to 22.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $142.66 but also hit the highest price of $207.32 during that period. The average intraday trading volume for Abbvie Inc shares is 5.77 million. The stock is currently trading -1.00% below its 20-day simple moving average (SMA20), while that difference is down -5.94% for SMA50 and it goes to -1.45% lower than SMA200.
Abbvie Inc (NYSE: ABBV) currently have 1.77B outstanding shares and institutions hold larger chunk of about 72.95% of that.
The stock has a current market capitalization of $311.83B and its 3Y-monthly beta is at 0.56. PE ratio of stock for trailing 12 months is 61.54, while it has posted earnings per share of $2.87 in the same period. Its PEG reads 7.54 and has Quick Ratio of 0.54 while making debt-to-equity ratio of 11.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABBV, volatility over the week remained 1.65% while standing at 2.13% over the month.
Stock’s fiscal year EPS is expected to drop by -1.63% while it is estimated to increase by 11.27% in next year. EPS is likely to grow at an annualized rate of 8.16% for next 5-years, compared to annual growth of -5.77% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on November 22, 2024 offering an Outperform rating for the stock and assigned a target price of $206 to it. Coverage by Wolfe Research stated Abbvie Inc (ABBV) stock as an Outperform in their note to investors on November 15, 2024, suggesting a price target of $205 for the stock. On November 04, 2024, Argus Upgrade their recommendations, while on October 17, 2024, Bernstein Initiated their ratings for the stock with a price target of $203. Stock get a Buy rating from HSBC Securities on June 05, 2024.
